Disclosed are inorganic nanoparticle quantum dots that effectively kill Gram-positive and Gram-negative bacteria resistant to antibiotics and the treatment of infectious bacterial diseases using the same, and more particularly inorganic nanoparticle quantum dots introduced with a hydrophilic ligand having activity of killing multidrug-resistant bacteria (MDR) and the use thereof. The quantum dots are capable of effectively killing bacteria when used at a low concentration by optimizing the core bandgap thereof and also do not exhibit cytotoxicity, and are thus useful as an agent for preventing or treating infectious diseases caused by multidrug-resistant bacteria.

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

The present disclosure generally relates to compositions and methods for modulating mitochondrial dynamic and function in skin conditions.

Use of 10H-benzo[g]pteridine-2,4-dione derivatives as photosensitizers in the inactivation of microorganisms.

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

A platinum(IV) complex has the structure of Formula I.

##STR00001##

where X, X′, Y, Y′, and Z are each independently an electron donor ligand, R.sub.1˜R.sub.5 are each independently a functional group, L is the linker unit, and n is selected from the group of 0, a positive charge, and a negative charge. Various methods contain steps for manufacturing the platinum(IV) complex, for treating cancer, a tumor, or an infection in a subject with the platinum(IV) complex. A pharmaceutical composition contains the platinum(IV) complex.

A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm.sup.2 and increases to a maximum dose of about 12 J/cm.sup.2.

The present disclosure relates to a novel compound for photodynamic therapy of cancer, a composition including the same, and a method for photodynamic therapy of cancer, and more specifically, a novel photosensitizer compound based on Nplmidazole having a C═S functional group introduced, a composition and sensor including the same and a method for photodynamic therapy using the same.

Methods for evaluating micrometastases in a tissue region of a subject are described. The methods include administering to the subject a detectably effective amount of a tumor-targeted photoactivatable immunoconjugate; allowing a sufficient amount of time for the tumor-targeted photoactivatable immunoconjugate to enter micrometastases in the tissue region; illuminating the tumor-targeted photoactivatable immunoconjugate; obtaining an image of the tissue region of the subject using a fluorescent imaging device, and evaluating the micrometastases in the tissue region by conducting algorithmic analysis of the image. Methods of treating micrometastases in a tissue region of a subject are also described.

The present invention includes a novel means for destroying aggressive mold in a system. A foreign target antagonist both draws and depletes defense mechanisms for the mold at which point the mold may be attacked with conventional anti-fungal preparations. A more preferred means for destroying the mold includes the post-depletion application of a mold indirect antagonist adapted to ameliorate cellular organelle deformation in the organism. In this preferred means, the organism overcomes the mold with its inherent biodefense mechanisms.